Synlogic raises$40M in Series B

What does Synlogic do?

Synlogic, is a privately held biopharmaceutical company which develops novel medicines. This biotech company leverages very advance technology platform available for creating synthetically engineered, therapeutic microbes with the potential of making significant advancements in the disease treatment.  The company is developing novel medicines based on the proprietary microbiome and synthetic biology platform. The company is pioneering at the convergence of these platforms. It has an approach for develop designer probiotics through precision molecular programming for treating human diseases which is exciting. It has the potential of revolutionizing the treatment for many medical conditions.

How much Synlogic was funded?

Synlogicraised$40M in Series B on February 17, 2016 from OrbiMed HealthCare Fund Management.

Previous funding

• $29.4M in Series A on July 22, 2014 from New Enterprise Associates and Atlas Venture
• $5M in Series A on October 7, 2014 from Bill & Melinda Gates Foundation

What is next for Synlogic?

Synlogic has raised a total of  $74.4M investments to date. The company is very pleased with the strong interest in the latest financing round from the leading life science investors. The funds will be used for supporting the development efforts of the company’s 2 lead inborn errors of metabolism program, PKU and UCD, which the company has plans of advancing to the clinic in early next year. The company also has plans to expand its pipeline of Synthetic Biotics across many therapeutic fields. The company has a new board of director, Mr.ChauQ.Khuong, OrbiMed’s private equity partner, who joined as a part of the new funding.

More about Synlogic

Synlogic was founded in 2014 by Timothy Lu, Ankit Mahadevia and Jim Collins. The company has its headquarters in Cambridge, MA. The company is backed by leading life sciences investors, including Orbimed, Atlas Venture,Deerfield, New Enterprise Associates (NEA) and Bill & Melinda Gates Foundation.